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Despite substantial progress in the development of antiretroviral regimens that durably suppress Human
Immunodeﬁciency Virus (HIV) infection, new agents that maintain high efﬁcacy while further optimizing
the safety of lifelong, chronic therapy are needed. Tenofovir alafenamide (TAF; formerly known as GS-
7340) is a novel prodrug of the antiviral acyclic nucleoside phosphonate tenofovir (TFV) with
improved properties relative to tenofovir disoproxil fumarate (TDF). Although potent and generally well
tolerated, TDF therapy has been associated with changes in markers of renal function, decreases in bone
mineral density and a rare occurrence of serious renal adverse events, including Fanconi's Syndrome. The
renal and bone toxicity observed with TDF is associated with high circulating plasma levels of TFV. TAF
was discovered to be a more efﬁcient prodrug able to further reﬁne HIV therapy and better address life-
long therapy in an older and increasingly comorbid HIV infected population. By enhancing stability in
biological matrices while being rapidly activated in cells, TAF produces higher levels of intracellular TFV
diphosphate, the pharmacologically active metabolite, in HIV-target cells at substantially reduced oral
doses of TFV equivalents. All TFV released in the body is eventually eliminated renally; therefore,
lowering the TFV equivalents administered reduces off-target kidney exposure. Effective therapy is thus
achieved at approximately 90% lower systemic exposure to TFV, translating to statistically and clinically
signiﬁcant improvement in safety parameters associated with bone mineral density and markers of renal
function.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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1.1. Frontiers in HIV therapy
Highly active antiretroviral therapy (HAART) has greatly
reduced morbidity and mortality in patients living with HIV (The
Antiretroviral Therapy Cohort Collaboration, 2008; Kitahata et al.,
2009; Mocroft et al., 1998; Palella et al., 1998). Despite the impact
of HAART, mortality in successfully treated HIV infected patients
remains higher than in the general uninfected population
(Bhaskaran et al., 2008; Losina et al., 2009; Nakagawa et al., 2012).
The effects of persistent inﬂammation and drug toxicity on
comorbidities that are considered non-HIV related, including
metabolic, cardiovascular and renal disease, contribute to these
differences in the health of infected individuals. Even in the face of
successful viral suppression, markers of inﬂammation (e.g., inter-
leukin 6, C-reactive protein) are elevated in HIV infected patients
and have been linked to an increase in type-2 diabetes and
hyperlipidemia resulting in a higher prevalence of cardiovascular
and kidney disease (De Wit et al., 2008; El-Sadr et al., 2006; Gupta
et al., 2015a; McComsey et al., 2014; Samaras, 2012). Further, a
number of the drugs used as part of HAART, particularly those
associated with dyslipidemia andmitochondrial toxicity, have been
found to increase the risk of non-HIV related disease (De Wit et al.,
2008; Friis-Moller et al., 2003). In order to further advance therapy,
new agents are needed that have minimal impact on comorbidities
and maximize long-term tolerability in the context of earlier
diagnosis, earlier initiation and longer duration of treatment, and
older age.1.2. Tenofovir
The anti-HIV activity of the acyclic nucleoside phosphonate
tenofovir (TFV; structures of TFV and its prodrugs are presented in
Fig. 1) was reported in 1993 (Balzarini et al., 1993). Subsequent
studies showed that the pharmacologically active diphosphate
metabolite (TFV-DP; an analog of 20-deoxyadenosine-triphosphate)
is a potent inhibitor of HIV reverse transcriptase with an inhibition
constant (Ki) in biochemical assays with an RNA template of
0.022 mM (Cherrington et al., 1995), and remained active against
drug resistant variants including the observation of hypersensi-
tivity by the methionine to valine mutation at 184 (M184V) that is
resistant to lamivudine and emtricitabine (Wainberg et al., 1999).
Moreover, TFV-DP is an exceedingly poor substrate and inhibitor ofFig. 1. Structures of acyclic nucleoside phosphonate tenofovir (TFV) and its lipophilic prod
namide (TAF).the mitochondrial DNA polymerase g with an incorporation efﬁ-
ciency 11,400-fold less than the natural substrate 20-deoxy-
adenosine triphosphate and a Ki of 59.5 mM (Cherrington et al.,
1995; Johnson et al., 2001). Consistent with biochemical results,
TFV did not selectively deplete mitochondrial DNAwhen incubated
with cells at up to 300 mM for up to 3 weeks in vitro (Birkus et al.,
2002; Venhoff et al., 2007). TFV-DP also has a long intracellular
half-life measured to be 150 h in peripheral blood mononuclear
cells (PBMC) isolated from patients (Hawkins et al., 2005; Pruvost
et al., 2005). Despite these favorable properties, TFV in parent
form could never be an orally administered drug. TFV is a dianion at
physiological pH and suffers from poor membrane permeability, as
reﬂected in its poor in vitro anti-HIV activity in cell-based assays,
and low oral bioavailability (Shaw et al., 1997).1.3. Tenofovir disoproxil fumarate
The disoproxil prodrug was found to have substantially
improved cell permeability and anti-HIV activity in vitro (Robbins
et al., 1998), increased oral bioavailability in animals (Shaw et al.,
1997), and more efﬁcient loading of PBMC relative to parenteral
TFV observed in vivo (Durand-Gasselin et al., 2009; Lee and Martin,
2006). Based on its improved properties, TFV disoproxil formulated
as the fumarate salt (TDF) was the ﬁrst selected for clinical devel-
opment and was ultimately approved by the US Food and Drug
Administration in 2001, the EuropeanMedicines Evaluation Agency
in 2002, and was subsequently approved in other countries around
the world. TDF administered at a dose of 300 mg has been used
extensively (over 9million patient years) as the preferred backbone
of HIV combination therapy. Integral to the clinical success of TDF
has been the low rates of discontinuations due to TFV-related viral
resistance or toxicity. However, while TDF therapy is generally well
tolerated it has been associated with effects on renal function and
bone mineral density.1.4. Goal of this review
Other prodrugs of TFV have been assessed in the interest of
further reﬁning long-term therapy and to allow for use in the
broadest population of those infected with HIV to determine if
more efﬁcient delivery of TFV to HIV-target tissues could be ach-
ievedwhile reducing off-target exposure, particularly to the kidney.
One of these prodrugs, tenofovir alafenamide (TAF) was selected for
further study based on its favorable properties and will be therugs tenofovir disoproxil administered as its fumarate salt (TDF) and tenofovir alafe-
Table 1
In vitro activity and stability of TFV and its prodrugs TDF and TAF.
TFV TDF TAF
EC50 HIV-1 (mM) 5.0 0.05 0.005
Half-life (min) stable 0.41 90
Results summarized from Lee et al. (Lee et al., 2005).
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clear and concise review of the mechanism of action and unique
pharmacology of TAF, and how it has translated into clinical proof of
concept for efﬁcacy and reduced off-target TFV-related effects in
clinical studies conducted to date.
2. Tenofovir disoproxil fumarate associated toxicity
2.1. Effects on bone and kidney
Nonclinical studies in mice, rats, dogs and monkeys identiﬁed
the kidney (increased serum creatinine, blood urea nitrogen,
hypophosphatemia, glucosuria, proteinuria, phosphaturia and cal-
ciuria at exposure of 2e20 times those observed in the clinic) and
bone (osteomalacia and decreased bone mineral density at expo-
sures greater than or equal to 6-fold those observed in patients) as
target organs (Viread prescribing information; http://www.gilead.
com/~/media/ﬁles/pdfs/medicines/hiv/viread/viread_pi.pdf?
la¼en). The clinical safety proﬁle of TDF with respect to renal
function and bone health has been the subject of comprehensive
reviews by Sax (Sax et al., 2007) and Powderly (Powderly, 2012).
Brieﬂy, clinical trials have identiﬁed an impact on renal function
and bone turnover in treatment arms with TDF-containing regi-
mens. Prospective studies have demonstrated greater loss of kidney
function and a higher risk of acute renal failure in patients receiving
TDF-based therapies versus non-TDF regimens (Cooper et al., 2010).
For example, in a combined analysis of Studies 903 and 934,
comparing TDF therapy to a thymidine analog, the TDF containing
regimen was found to have a small but statistically signiﬁcant
greater decrease in the estimated glomerular ﬁltration rate (Gallant
et al., 2008). In post-marketing experience from the Viread
Expanded Access Program renal failure, Fanconi's Syndrome or
tubular dysfunction, and elevated serum creatinine were rare ac-
counting for 0.3%, 0.05% and 0.1%, respectively, of patients (Nelson
et al., 2007). Importantly, increased levels of serum creatinine and
the risk of renal adverse events have been associated with the
higher levels of plasma TFV observed when TDF is given with HIV
protease inhibitors or pharmacoenhancers, inhibitors of the intes-
tinal efﬂux of TDF (Tong et al., 2007), suggesting a link between
plasma TFV exposure and the effect on proximal tubule function
(Gallant and Moore, 2009; Nelson et al., 2007). In a large cohort of
HIV-1 infected veterans, TFV exposure was independently associ-
ated with proteinuria, more rapid eGFR decline, and the develop-
ment of eGFR <60 ml/min (Scherzer et al., 2012). TDF-related
nephrotoxicity has identiﬁed risk factors, including older age, un-
derlying renal disease and other co-morbidities, and regimens
containing ritonavir-boosted protease inhibitors (Morlat et al.,
2013; Nelson et al., 2007).
While the increased prevalence of osteopenia and osteoporosis
in patients with HIV infection is multifactorial (Brown and Qaqish,
2006; Grund et al., 2009), initiation of TDF-containing antiretro-
viral therapy leads to a larger reduction in bone mineral density
than regimens not containing TDF (Mateo et al., 2014; Bernardino
et al., 2015). In Study 903, TDF resulted in slightly greater de-
creases in bone mineral density at the lumbar spine but not hip
relative to stavudine and these changes correlated with biochem-
ical markers of bone turnover including elevated levels of para-
thyroid hormone and 1,25 vitamin D (Gallant et al., 2004; Viread
Prescribing Information). The etiological mechanism for the effects
on bone has not been established but an in vitro study found no
evidence for a direct effect of TFV on osteoblasts (Liu et al., 2013).
While a deﬁnitive relationship with TDF use and increased clinical
events has not been established, a large observational study done
with the Veterans Affairs' Clinical Case Registry from 1988 to 2009
found that cumulative TDF exposure was associated with anincreased rate of fractures (Bedimo et al., 2012). These ﬁndings
could lead to concern in prescribing TDF containing regimens to
those with preexisting or who are at increased risk for bone con-
ditions (e.g., osteoporosis).2.2. Mechanism for tenofovir renal accumulation
TFV is renally eliminated by the combined action of active
tubular secretion in the proximal tubule and passive glomerular
ﬁltration. Active tubular secretion is mediated by uptake by the
organic anion transporters (OAT) 1 and 3 and efﬂux by the multi-
drug resistance-related protein (MRP) 4 (Cihlar et al., 2001; Ray
et al., 2006). Renal accumulation of TFV and the resulting effects
on the function of the proximal tubule are caused by highly efﬁcient
uptake from plasma and less rapid efﬂux into urine. The relation-
ship of counterbalancing transport processes on intracellular
accumulation of TFV and toxicity has been nicely illustrated in vitro
by experiments showing that overexpression of OAT1 and OAT3
increases cytotoxicity while co-transfection of MRP4 causes an in-
cremental decrease in the effects (Stray et al., 2013).3. Mechanism of action
3.1. In vitro studies
TAF was identiﬁed as an alternate TFV prodrug to TDF that more
efﬁciently loads HIV-target cells (Lee et al., 2005). As summarized
in Table 1, TAF is 1000- and 10-fold more active against HIV in vitro
than TFV or TDF, respectively. Reﬂecting the release of the same
pharmacologically active metabolite, TAF has the same resistance
proﬁle as TFV and TDF in vitro but the higher PBMC levels achieved
after TAF administration relative to TDF in patients (discussed
further below) suggest better coverage of resistance mutations in
the clinic (Margot et al., 2015). Stability in biological matrices,
including plasma, and selective intracellular cleavage of TAF allows
for prolonged systemic exposure to intact prodrug and the accu-
mulation of higher intracellular levels of the pharmacologically
active metabolite TFV-DP relative to TDF. The mechanism of cell
loading by TAF has been extensively studied in vitro and is sum-
marized in Fig. 2. In whole blood, TAF was found to preferentially
load PBMC over red blood cells and formation of TFV and its
phosphorylated metabolites was preceded by the intracellular
formation of the key intermediate TFV alanine (Eisenberg et al.,
2001). Studies in isolated cells have shown efﬁcient TAF activa-
tion and potent antiviral activity in the HIV-target cells CD4þ T-
cells and monocyte derived macrophages (Bam et al., 2014a). The
lysosomal carboxypeptidase cathepsin A (CatA) was identiﬁed as
the primary hydrolase catalyzing the initial step in intracellular
activation of TAF in HIV-target cells (Birkus et al., 2007). CatA is a
ubiquitously expressed enzyme including high levels in lymphoid
cells (Satake et al., 1994). With the exception of the covalent pro-
tease inhibitors of hepatitis C virus telaprevir and boceprevir that
nonspeciﬁcally inhibit CatA, TAF intracellular activation and anti-
viral activity is not adversely affected by concomitant agents
including HIV protease inhibitors and other HCV protease in-
hibitors (Birkus et al., 2015; Callebaut et al., 2015). The rapid initial
Fig. 2. Mechanism of HIV-target cell loading by TAF. TAF enters cells passively where it is subject to ester hydrolysis by the lysosomal carboxypeptidase cathepsin A (CatA).
Following chemical release of phenol from an unstable metabolite, a key intermediate metabolite is formed with alanine conjugated to TFV. Alanine is released either by enzymatic
or chemical degradation to release TFV that is subsequently phosphorylated to the pharmacologically active metabolite TFV-DP. TFV is slowly released from cells into plasma where
it is eliminated from the body renally.
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creates a sink causing marked loading during TAF exposure and,
coupled with the formation of poorly permeable metabolites that
are effectively trapped in cells, allows for substantial accumulation
of the pharmacologically active metabolite TFV-DP.3.2. Nonclinical pharmacokinetics and distribution
In order to establish the effect of the cellular pharmacology
described above in vivo, pharmacokinetic studies assessing plasma
and PBMC levels were completed in dogs (Babusis et al., 2013; Lee
et al., 2005). Unlike TDF, these studies found measurable levels of
circulating TAF in plasma.While TAFwas only transiently present in
plasma (t1/2 ~30 min), the exposure was sufﬁcient to drive high and
persistent levels of TFV-DP in PBMCs while only resulting in low
levels of TFV in plasma. The relative efﬁciency of cell loading by TAF
was assessed following administration of equivalent doses of sub-
cutaneous TFV, oral TDF or oral TAF in dogs (Lee et al., 2005). The
PBMC to plasma ratio were approximately 1, 5 and 140 for TFV, TDF
and TAF, respectively, illustrating that TAF is highly efﬁcient at
concentrating TFV and its metabolites in PBMC. More broadly, oral
TAF administration also resulted in higher levels relative to TDF in
on-target tissues including lymph nodes (iliac, axillary, inguinal
and mesenteric; 5.7- to 15-fold) and spleen (12.8-fold) in dogs. In
contrast, TAF did not more efﬁciently load the kidney and, subse-
quently, has been shown not to be a substrate for renal uptake
transporters (Bam et al., 2014b). Taken together, these results
suggested that lower doses of TAF could be administered clinically,
resulting in similar or even increased levels of TFV and its metab-
olites in HIV-target cells while markedly reducing off-target
exposure to the kidney.4. Proof of concept
4.1. Antiviral potency
Monotherapy studies were completed in treatment naïve HIV
infected subjects to establish clinical proof of concept that TAF
achieves enhanced antiviral potency at a greatly reduced dose
relative to TDF. An initial study reported by Markowitz et al.
assessed doses of 40 and 120 mg of TAF relative to TDF following 14
days of administration (Markowitz et al., 2014). These doses of TAF
proved to be substantially more potent than the clinically used dose
of 300 mg TDF with mean changes in HIV RNA of 0.94, 1.57,
and 1.71 log10 copies/mL in the 300 mg TDF, 40 mg TAF and
120 mg TAF groups, respectively. Therefore, a subsequent study
assessed the antiviral activity of TAF at 8, 25 and 40 mg relative to
300 mg TDF following 10 days of monotherapy (Ruane et al., 2013).
It was found that 8 mg of TAF showed similar anti-HIV activity to
300 mg of TDF and at 25 mg, approximately 1/10th the TFV
equivalents administered with the clinical dose of TDF, a statisti-
cally signiﬁcant greater anti-HIV activity was achieved compared to
TDF (1.46 versus 0.97 log10 copies/mL; P ¼ 0.024) at a dose
resulting in 86% lower plasma TFV. Consistent with more potent
HIV activity, PBMC levels were 7-fold higher at 25 mg TAF relative
to 300 mg TDF. The pharmacokinetic proﬁle in patients was
consistent with that observed nonclinically in dogs. These studies
established the dose of 25 mg TAF for further clinical development.
Table 2 summarizes how TFV administration has been reﬁned from
the original study of 1 mg/kg intravenous TFV, reported in 1998 by
Deeks et al. (Deeks et al., 1998), to the approved dose of 300mg TDF,
and, ﬁnally, to 25 mg TAF. In short, increasing antiviral activity has
been achieved with lower plasma TFV through the administration
of increasingly more efﬁcient prodrugs. The improved stability of
Table 2
Mean Pharmacokinetic and antiviral parameters Following 7 (TFV) or 10 days (TDF and TAF) of monotherapy in HIV-1 infected patients.
Dose (mg) Plasma TFV DViral load from baseline (log10 copies/ml)
Cmax (ng/ml) AUCtau (ngCh/ml)
TFV (intravenous) 1 per kg 2500 4800 0.60
TDF (oral) 300 250 1900 0.97
TAF (oral) 25 16 270 1.46
Results reported previously (Deeks et al., 1998; Ruane et al., 2013).
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edly lower dose, with correspondingly reduced levels of plasma
TFV, while maintaining high levels of TFV-DP in HIV-target tissues
and, resulting, potent antiviral activity (Fig. 3).4.2. Efﬁcacy
The efﬁcacy of low dose TAF has been conﬁrmed in 4 separate
patient populations: treatment naive adults, treatment naive ado-
lescents, treatment experienced adults following switch, and renal
impairment. For example, in phase 2 and 3 clinical studies where
10 mg TAF (dose of TAF when administered with a pharma-
coenhancer that inhibits intestinal efﬂux and increase TAF oral
absorption as reported by Lepist et al. (Lepist et al., 2012)) showed
similar viral response as 300 mg TDF when coformulated with
emtricitabine/elvitegravir/cobicistat (E/C/F/TAF) (Sax et al., 2015,
2014). The E/C/F/TAF ﬁxed dosed combination has demonstrated
potent and durable anti-retroviral activity in two Phase 2 studies
(Sax et al., 2014; Mills et al., 2015b), and six Phase 3 studies (Gupta
et al., 2015b; Kizito et al., 2015; Mills et al., 2015a; Pozniak et al.,
2015; Sax et al., 2015). Using the FDA-deﬁned snapshot method-
ology at Week 48, E/C/F/TAF was noninferior to standard of care
based regimens in the active comparator studies. Results were
consistently strong across multiple treatment populations. While
resistance to study treatment was not observed in E/C/F/TAF arm of
the Phase 2 trial, in the two larger studies a small percentage of
patients (<1% in both arms) did develop drug resistance to some of
the treatments, most commonly the M184V mutation selected by
emtricitabine. The virologic success rates at Week 48 for E/C/F/TAF
in naive subjects were greater than 90%, among the highest seen in
clinical trials in naive HIV-1 infected adult subjects, demonstrating
the potent antiviral efﬁcacy of the E/C/F/TAF ﬁxed dose combina-
tion against a highly active comparator. Similar response rates be-
tween TAF and TDF arms were also observed in protease inhibitorFig. 3. Comparison of the efﬁciency of HIV-target cell delivery following oral admin-
istration of tenofovir prodrugs. Oral administration of TAF at 25 mg, 1/10th the molar
equivalents of TFV present in 300 mg TDF, results in 90% lower systemic levels of TFV
while maintaining intracellular levels of the pharmacologically active metabolite TFV-
DP in HIV-target cells.based single tablet regimen study of TAF coformulated with dar-
unavir/cobicistat/emtricitabine (D/C/F/TAF) (Mills et al., 2015b).4.3. Safety
TFV is cleared entirely by renal elimination. Therefore, reducing
the TFV-equivalents administered and, resulting, circulating levels
of TFV to approximately 1/10th those observedwith TDF results in a
corresponding reduction in TFV exposure to the kidney. The avail-
ability of 48 week results from >1000 patients receiving TAF in
controlled, head-to-head with TDF, Phase 2 and 3 studies allows for
the ﬁrst assessment of whether the reduced off-target exposure to
TFV impacts safety and tolerability in a clinically meaningful way
(Gupta et al., 2015b; Mills et al., 2015a,b; Pozniak et al., 2015; Sax
et al., 2015, 2014). These studies consistently showed TAF to have
a reduced impact on bone mineral density and markers of renal
function.
In the phase 3 studies, E/C/F/TAF had statistically signiﬁcantly
smaller increases in serum creatinine and corresponding decreases
in estimated glomerular ﬁltration rate, less proteinuria and albu-
minuria, smaller decreases in bone mineral density in treatment
naïve patients and increased bone mineral density in treatment
experienced patients switching from a TDF-containing regimen.
More speciﬁcally with regard to bone, TAF was found to have sta-
tistically signiﬁcant less decrease in mean bone mineral density
than TDF at 48 wk at the spine (1.30 versus 2.86; p < 0$0001)
and hip (0.66 versus2.95; p < 0$0001). Furthermore, changes in
bone mineral density in the TAF group were numerically similar to
those generally reported after initiation of antiretroviral therapy
including with non-TDF containing regimens (Grund et al., 2009;
Sax et al., 2015). Consistent with the phase 3 ﬁndings, phase 2
studies with both integrase and protease containing regimens
found a highly statistically signiﬁcant difference (P < 0.001) be-
tween TAF and TDF on their impact on markers for bone formation
(procollagen Type 1 N-terminal propeptide) and reabsorption (C-
terminal telopeptide) (Mills et al., 2015b; Sax et al., 2014). Highly
statistically signiﬁcant differences (P < 0.01) were observed across
all studies for markers of proximal tubule function, b2 micro-
globulin and retinol binding protein. Furthermore, patients
switching from a TDF containing regimen to a TAF containing
regimen had signiﬁcant improvements in urinary biomarkers and
bone mineral density (Gupta et al., 2015b; Mills et al., 2015a,b).
Impressively, patients with renal impairment switching from a TDF
containing regimen to a TAF containing regimen had statistically
signiﬁcant increases in bone mineral density at the spine (2.95%)
and hip (1.85%) after 48 weeks (Gupta et al., 2015b).
Increases in low-density lipo-protein (LDL), high-density lipo-
protein (HDL) and triglycerides were greater with TAF than TDF in
Phase 2 and 3 studies suggesting that TAF does not have the same
cholesterol lowering effect as has been reported for TDF in HIV
infected patients and uninfected subjects receiving pre-exposure
prophylaxis (e.g., ACTG5206 study (Tungsiripat et al., 2010) and
iPrEx (Mulligan et al., 2013)). These results support the conclusion
that lipid effects are off-target and caused by an as yet unknown
A.S. Ray et al. / Antiviral Research 125 (2016) 63e7068mechanism related to higher systemic levels of TFV. However, the
total cholesterol to HDL ratio was not different between the groups
indicating no effect on overall cardiovascular risk. No new TFV-
related adverse effects were identiﬁed.
5. Conclusion
TAF is more efﬁcient than TDF in delivering TFV into HIV-target
cells. Nonclinical mechanistic studies were successfully translated
into the clinic where TAF, at approximately 1/10th the TFV-
equivalent dose and plasma TFV exposure, resulted in higher
TFV-DP levels in HIV target cells, leading to greater monotherapy
activity. When co-formulated as E/C/F/TAF in a single tablet
regimen, high clinical efﬁcacy was demonstrated in a broad phase 3
program in which treatment-naïve adults and adolescents, and
treatment-suppressed adults with normal kidney function and
renal impairment, were evaluated. Most importantly TAF had a
reduced impact on renal function and bone mineralization as
consistently demonstrated by multiple parameters during clinical
studies. The improved safety proﬁle of TAF allows for a broader
population of HIV-infected individuals to potentially beneﬁt from
TFV-based regimens. This includes patients at risk for renal and
bone disease, and adolescents who have not yet reached peak bone
mass. The low dose and improved safety proﬁle of TAF also have
implications for the effective treatment of HIV in resource limited
settings where regular safety monitoring is not possible. Further
studies are also under way to assess the potential of TAF in other
indications where TDF-based therapy has been approved including
pre-exposure prophylaxis and hepatitis B virus (HBV) infection. A
long-acting subdermal implant of TAF has been assessed in dogs
and discussed by the authors of the article as a potential modality
for pre-exposure prophylaxis (Gunawardana et al., 2015). In the
context of HBV therapy, nonclinical studies have shown TAF is also
more effective at delivering TFV-DP into the liver than TDF
(Murakami et al., 2015), a clinical study has established potent anti-
HBV activity at doses as low as 8 mg in a Phase 1b clinical study
(Agarwal et al., 2015), and TAF is currently in Phase 3 clinical trials
for the treatment of HBV. In conclusion, TAF is a promising new
therapeutic agent for the lifelong treatment of HIV that maintains
high potencywhile signiﬁcantly improving the safety proﬁle of TDF.
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